News

The American Parkinson Disease Association (APDA) is collaborating with Smart Patients — an online community connecting Parkinson’s patients and their families — to extend APDA’s resources to help people living with the disease. Smart Patients provides resources so people can have the latest information related to their condition, share their questions and…

Acorda Therapeutics will soon release novel data on its Phase 3 SPAN-PD trial (Study 004, NCT02240030) investigating the experimental drug Inbrija (CVT-301) as a potential therapy for patients with Parkinson’s disease. Acorda presents its poster, “Inhaled levodopa (CVT-301, 84-mg dose) significantly improves motor function during OFF periods in Parkinson’s disease…

Researchers from North Wales received a £33,000 (about $43,000) award to study the potential benefits of brain-stimulating computer games in the treatment of Parkinson’s disease.  The scientific study titled, “Early stage feasibility assessment of a non-pharmacological intervention for motor…

Experts from ATCC — a leading nonprofit repository of biological materials — partnered with the Michael J. Fox Foundation for Parkinson’s Research for a workshop at the recent International Society for Biological and Environmental Repositories (ISBER) 2017 Annual Meeting. The workshop aimed to address best practices for providing…

Italian researchers found that when used along with standard medication, Normast (ultra-micronized palmitoylethanolamide, or um-PEA) helped lower both motor and non-motor symptoms in patients with advanced Parkinson’s disease (PD), and slowed disease progression and disability. The study, “Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease,” appeared in the journal CNS…